Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04573231
Phase: PHASE2
Trial Summary: The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive me – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Wisconsin, Madison
Acronym:

Pin It on Pinterest